These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33660941)

  • 1. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis.
    Lin C; Hu F; Chu H; Ren P; Ma S; Wang J; Bai J; Han X; Ma S
    Thorac Cancer; 2021 Apr; 12(7):1084-1095. PubMed ID: 33660941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
    Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
    Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
    Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
    BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
    Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
    [No Abstract]   [Full Text] [Related]  

  • 8. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    Frampton JE
    Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
    Spaans JN; Goss GD
    Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Adjuvant First-Generation TKIs versus Chemotherapy in Patients with Completely Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis.
    Shen B; Wu D; Liu J; Yang Y
    Cancer Invest; 2024 Jan; 42(1):63-74. PubMed ID: 38224061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
    Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
    Zhao N; Wu ZP; Yang J; Feng WN; Yang SL; Luo Y; Ye J; Wang F; Zhang XW; Xiao Y; Wu LL; Gu WQ
    World J Surg Oncol; 2023 Feb; 21(1):45. PubMed ID: 36782320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
    Yan H; Li Q; Wang W; Zhen H; Cao B
    Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer.
    Cui R; Wei C; Li X; Jiang O
    Medicine (Baltimore); 2022 Nov; 101(47):e31894. PubMed ID: 36451449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
    Yin Q; Xun X; Yang G; Cui H; Liu H
    Oncol Res Treat; 2021; 44(6):344-353. PubMed ID: 33951671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.